IRIS
RICCIO, ELEONORA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.560
AS - Asia 4.237
EU - Europa 2.837
SA - Sud America 467
Continente sconosciuto - Info sul continente non disponibili 249
AF - Africa 131
OC - Oceania 4
AN - Antartide 1
Totale 12.486
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.367
SG - Singapore 1.774
RU - Federazione Russa 1.304
VN - Vietnam 978
CN - Cina 810
IT - Italia 716
BR - Brasile 347
HK - Hong Kong 227
DE - Germania 155
FR - Francia 153
CA - Canada 109
IE - Irlanda 85
GB - Regno Unito 81
FI - Finlandia 76
NL - Olanda 76
BD - Bangladesh 73
IN - India 67
JP - Giappone 67
MX - Messico 54
AR - Argentina 49
CI - Costa d'Avorio 40
UA - Ucraina 40
ZA - Sudafrica 37
KR - Corea 34
PL - Polonia 31
SE - Svezia 23
IQ - Iraq 22
EC - Ecuador 21
TH - Thailandia 21
PH - Filippine 19
ES - Italia 17
ID - Indonesia 15
PK - Pakistan 15
TR - Turchia 15
CO - Colombia 12
MY - Malesia 12
AT - Austria 11
BG - Bulgaria 11
RO - Romania 10
TW - Taiwan 10
NP - Nepal 9
UZ - Uzbekistan 9
VE - Venezuela 9
KE - Kenya 8
TN - Tunisia 8
UY - Uruguay 8
EG - Egitto 7
IL - Israele 7
KG - Kirghizistan 7
LT - Lituania 7
MA - Marocco 7
PE - Perù 7
CH - Svizzera 6
AE - Emirati Arabi Uniti 5
CL - Cile 5
CR - Costa Rica 5
DZ - Algeria 5
KZ - Kazakistan 5
SA - Arabia Saudita 5
BE - Belgio 4
BO - Bolivia 4
ET - Etiopia 4
GE - Georgia 4
IR - Iran 4
JM - Giamaica 4
JO - Giordania 4
NG - Nigeria 4
NO - Norvegia 4
BS - Bahamas 3
CZ - Repubblica Ceca 3
DK - Danimarca 3
EU - Europa 3
KH - Cambogia 3
MN - Mongolia 3
PT - Portogallo 3
AL - Albania 2
AM - Armenia 2
AU - Australia 2
AZ - Azerbaigian 2
BH - Bahrain 2
BJ - Benin 2
DO - Repubblica Dominicana 2
EE - Estonia 2
GR - Grecia 2
GY - Guiana 2
HN - Honduras 2
LA - Repubblica Popolare Democratica del Laos 2
LV - Lettonia 2
PA - Panama 2
PY - Paraguay 2
SK - Slovacchia (Repubblica Slovacca) 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
AD - Andorra 1
AI - Anguilla 1
AO - Angola 1
AQ - Antartide 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BZ - Belize 1
Totale 12.213
Salva come PNG Salva come JPEG
Città #
Singapore 822
San Jose 715
Ashburn 392
Moscow 308
Beijing 280
Ho Chi Minh City 243
Chandler 223
Hong Kong 214
Hanoi 181
Council Bluffs 166
Santa Clara 153
Hefei 148
Napoli 129
Dong Ket 124
Naples 122
Los Angeles 116
Lauterbourg 85
Millbury 82
The Dalles 67
New York 65
Munich 59
Tokyo 57
Amsterdam 55
Des Moines 55
Dublin 53
Haiphong 47
Boston 46
Nanjing 42
Buffalo 41
Da Nang 41
Princeton 41
Redondo Beach 41
São Paulo 41
Orem 34
Phoenix 34
Montreal 33
Dallas 32
Lawrence 32
Milan 28
Caserta 27
Wilmington 27
Warsaw 26
Atlanta 25
Seoul 25
Seattle 24
Washington 24
Mexico City 23
Buenos Aires 22
Frankfurt am Main 21
Helsinki 21
Toronto 21
Rome 20
Hải Dương 19
Johannesburg 19
London 19
Denver 18
Houston 18
Nuremberg 18
Turku 18
Biên Hòa 16
Chennai 16
Chicago 16
Jacksonville 15
Poplar 15
Ottawa 14
Stockholm 14
Bangkok 12
Brooklyn 12
Falkenstein 12
Hebei 12
Rio de Janeiro 12
Tianjin 11
Can Tho 10
Long Xuyen 10
Manchester 10
Nanchang 10
New Delhi 10
Redwood City 10
Sciacca 10
Sofia 10
Duncan 9
Düsseldorf 9
Jiaxing 9
Kuala Lumpur 9
San Francisco 9
Tashkent 9
Montevideo 8
Ninh Bình 8
Thái Bình 8
Belo Horizonte 7
Boardman 7
Brasília 7
Campinas 7
Fairfield 7
Nairobi 7
Querétaro 7
Quito 7
Tân Tiến 7
Vĩnh Long 7
Baghdad 6
Totale 6.293
Salva come PNG Salva come JPEG
Nome #
Il nefrologo nel trattamento dell’iperammoniemia da disordini del ciclo dell’urea 610
Late diagnosis of Fabry disease caused by a de novo mutation in a patient with end stage renal disease Case Reports 310
Evidence That p-Cresol and IL-6 Are Adsorbed by the HFR Cartridge: Towards a New Strategy to Decrease Systemic Inflammation in Dialyzed Patients? 196
Corpus callosum involvement: a useful clue for differentiating Fabry Disease from Multiple Sclerosis 195
Experimental evidence and clinical implications of Warburg effect in the skeletal muscle of Fabry disease 195
Alterations of functional connectivity of the motor cortex in Fabry disease: An RS-fMRI study 177
Diagnostic, Predictive, Prognostic, and Therapeutic Molecular Biomarkers in Third Millennium: A Breakthrough in Gastric Cancer 168
Pituitary function and morphology in Fabry disease. 164
Plasma p-cresol lowering effect of sevelamer in non-dialysis CKD patients: evidence from a randomized controlled trial 163
Striatonigral involvement in Fabry Disease: A quantitative and volumetric Magnetic Resonance Imaging study 157
Cardiopulmonary determinants of reduced exercise tolerance in Fabry disease 157
Plasma p-Cresol Lowering Effect of Sevelamer in Peritoneal Dialysis Patients: Evidence from a Cross-Sectional Observational Study. 156
6-tips diet: a simplified dietary approach in patients with chronic renal disease. A clinical randomized trial 156
Current tissue molecular markers in colorectal cancer: A literature review 155
Nutritional management in renal transplant recipients: A transplant team opportunity to improve graft survival 155
Parapelvic cysts, a distinguishing feature of renal Fabry Disease. 153
RAAS Inhibitor Prescription and Hyperkalemia Event in Patients With Chronic Kidney Disease: A Single-Center Retrospective Study 152
Immunosuppression and multiple primary malignancies in kidney transplanted patients. A single-institute study 151
Absence of infratentorial lesions in Fabry disease contributes to differential diagnosis with multiple sclerosis 151
Cerebrovascular and Brain Abnormalities In Autosomal-Dominant Polycystic Kidney Disease: Role Of 3d Time-of-Flight Magnetic Resonance Angiography 150
Hybrid positron emission tomography-magnetic resonance imaging for assessing different stages of cardiac impairment in patients with Anderson-Fabry disease: AFFINITY study group 149
Renal sympathetic-nerve ablation for uncontrolled hypertension in a patient with single-kidney autosomal dominant polycystic kidney disease. 149
The effects of somatostatin analogues on liver volume and quality of life in polycystic liver disease: a meta-analysis of randomized controlled trials 149
Effect of paricalcitol vs calcitriol on hemoglobin levels in chronic kidney disease patients: a randomized trial 148
Reduced intracranial volume in Fabry Disease: Evidence of abnormal neurodevelopment? 147
Parapelvic Cysts: An Imaging Marker of Kidney Disease Potentially Leading to the Diagnosis of Treatable Rare Genetic Disorders? A Narrative Review of the Literature 146
Effect of oral liposomal iron versus intravenous iron for treatment of iron deficiency anaemia in CKD patients: A randomized trial 146
Relationship between left ventricular diastolic function and myocardial sympathetic denervation measured by (123)I-meta-iodobenzylguanidine imaging in Anderson-Fabry disease 146
The central vein sign helps in differentiating multiple sclerosis from its mimickers: lessons from Fabry disease 145
Molecular Mechanisms of Renal Cellular Nephrotoxicity due to Radiocontrast Media 145
A strange epigastric pain. 145
ROLE OF HFR CARTRIDGE IN THE REMOVAL OF MEDIATORS OF INFLAMMATION IN HEMODIALYSIS PATIENTS 145
Identifying Fabry patients in dialysis population: prevalence of GLA mutations by renal clinic screening, 1995–2019 145
Default mode network modifications in Fabry disease: A resting-state fMRI study with structural correlations 143
Effects of switching from agalsidase Beta to agalsidase alfa in 10 patients with anderson-fabry disease. 141
Early Biomarkers of Fabry Nephropathy: A Review of the Literature. 141
Prevalence of GLA gene mutations and polymorphisms in patients with multiple sclerosis: A cross-sectional study 138
Oral Sucrosomial® iron versus intravenous iron for recovering iron deficiency anaemia in ND-CKD patients: a cost- minimization analysis. 138
Endothelial-mediated coronary flow reserve in patients with Anderson-Fabry disease 137
Genetic variants associated with gastrointestinal symptoms in Fabry disease. 134
Optical Coherence Tomography Angiography Findings in Fabry Disease 134
Fatigue as hallmark of Fabry disease: role of bioenergetic alterations 133
Prominent longitudinal strain reduction of left ventricular basal segments in treatment-naïve Anderson-Fabry disease patients 133
Familial polycystic kidneys with no genetic confirmation: Are we sure it is ADPKD? 131
ADPKD and metformin: from bench to bedside 131
Early Cardiac Involvement Affects Left Ventricular Longitudinal Function in Females Carrying α-Galactosidase A Mutation: Role of Hybrid Positron Emission Tomography and Magnetic Resonance Imaging and Speckle-Tracking Echocardiography 127
Stepwise shortening of agalsidase beta infusion duration in Fabry disease: Clinical experience with infusion rate escalation protocol 127
Methylome Profiling in Fabry Disease in Clinical Practice: A Proof of Concept 126
Clinical manifestation of patients with Fabry disease and R356W GLA variant 125
Therapeutic advances in ADPKD: the future awaits 124
Randomized Controlled Trials on Renin Angiotensin Aldosterone System Inhibitors in Chronic Kidney Disease Stages 3-5: Are They Robust? A Fragility Index Analysis 123
Assessing brain involvement in Fabry disease with deep learning and the brain‐age paradigm 123
Layer-specific longitudinal strain in Anderson–Fabry disease at diagnosis: A speckle tracking echocardiography analysis 123
Terapia enzimatica sostitutiva nella malattia di Fabry: cosa abbiamo imparato dallo switch? 121
Atrial septum aneurysm: an unusual manifestation in ADPKD? 119
Fabry's disease: a comparison of the effectiveness of two different enzyme replacement therapies 119
Molecular and clinical studies in five index cases with novel mutations in the GLA gene. 118
Tolvaptan vs. somatostatin in the treatment of ADPKD: A review of the literature 116
Role of serial cardiac 18F-FDG PET-MRI in Anderson-Fabry disease: a pilot study 114
Clinical and Pathophysiologic Correlates of Basilar Artery Measurements in Fabry Disease 113
Microstructural damage of the cortico-striatal and thalamo-cortical fibers in Fabry disease: a diffusion MRI tractometry study 111
Renal denervation in ADPKD: an exceptional case 111
Immunomodulatory Effect of Continuous Venovenous Hemofiltration during Sepsis: Preliminary Data 108
Multiple sclerosis and fabry Disease, two sides of the coin? The case of an Italian family 108
SWITCH TO AGALSIDASE ALFA AFTER THE SHORTAGE OF AGALSIDASE BETA IN FABRY DISEASE: A SYSTEMATIC REVIEW WITH METANALYSIS OF THE LITERATURE 107
Glomerular Hyperfiltration: An Early Marker of Nephropathy in Fabry Disease 104
Fanconi syndrome with lysinuric protein intolerance 102
Late diagnosis of Fabry disease caused by a de novo mutation in a patient with end stage renal disease. 102
Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial 102
The Retinal Vessel Density as a New Vascular Biomarker in Multisystem Involvement in Fabry Disease: An Optical Coherence Tomography Angiography Study 97
Octreotide-LAR in ADPKD patients with very low kidney function: a single-center real-life experience 93
Does Physical Exercise Ameliorate Chronic Kidney Disease-Related Complications? The Case of Anaemia and Chronic Kidney Disease-Mineral Bone Disorder 93
Cardiac involvement in Anderson–Fabry disease. The role of advanced echocardiography 92
A pilot study of circulating microRNAs as potential biomarkers of Fabry disease 92
Data on the assessment of LV mechanics by speckle tracking echocardiography in ADPKD patients 90
Cardiac sympathetic neuronal damage precedes myocardial fibrosis in patients with Anderson-Fabry disease 89
Liposomial iron: a new proposal for the treatment of anaemia in chronic kidney disease 88
Association between Left Atrial Deformation and Brain Involvement in Patients with Anderson-Fabry Disease at Diagnosis 87
Genetic variants associated with Fabry disease progression despite enzyme replacement therapy 83
Cholesterol crystal embolism treatment: from bench to bedside 82
Idiosyncratic hepatic toxicity in autosomal dominant polycystic kidney disease (ADPKD) patient in combined treatment with tolvaptan and amoxicillin/clavulanic acid: a case report. 81
Left ventricular dysfunction in ADPKD and effects of octreotide-LAR: A cross-sectional and longitudinal substudy of the ALADIN trial 80
Treatment with Agalsidase Alfa during Pregnancy in a Heterozygous Female with Fabry Disease 78
Does left ventricular function predict cardiac outcome in Anderson-Fabry disease? 78
New insights in efficacy of different ERT dosages in Fabry disease: Switch and switch-back studies data following agalsidase beta shortage. Update of systematic review 77
Atheroembolic Kidney Disease and Atypical Hemolytic Uremic Syndrome: Two Sides of the Same Coin? 75
Enzyme replacement therapy in patients with Fabry disease: state of the art and review of the literature 72
Polycystic pancake kidney 71
Semaglutide in Non-Diabetic Patients with Fabry Disease 71
Focal reduction in left ventricular 123I-metaiodobenzylguanidine uptake and impairment in systolic function in patients with Anderson-Fabry disease 71
Metformin in autosomal dominant polycystic kidney disease: experimental hypothesis or clinical fact? 68
Left ventricular radial strain impairment precedes hypertrophy in Anderson-Fabry disease 66
Nutritional treatment in chronic kidney disease: the concept of nephroprotection. 65
“Voclosporin in late onset lupus nephritis with anti-PLA2R antibodies” 60
The Case | A patient with autosomal dominant polycystic kidney disease with an atypical kidney magnetic resonance image 55
The potential use of biomarkers in predicting contrast-induced acute kidney injury. 55
Trimethoprim-sulfamethoxazole prophylaxis inantineutrophil cytoplasmic antibody-associatedvasculitis: watch out for pseudoacute kidney injury: comment on the article by Kim et al (Tme‐Dependent Effect of Prophylactic Trimethoprim‐Sulfamethoxazole on the Incidence of Serious Infections in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis: A Target Trial Emulation Study) 53
Acute Kidney Injury in COVID-19 Pandemic 52
Recommendations for the inclusion of Fabry disease as a rare febrile condition in existing algorithms for fever of unknown origin 47
Clinical outcomes in Fabry patients switching to agalsidase beta for renal ineffectiveness of the primary Fabry therapy: a single-centre analysis 21
Totale 12.465
Salva come PNG Salva come JPEG
Categoria #
all - tutte 38.974
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.974
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022446 0 0 5 4 7 11 28 18 33 52 116 172
2022/2023571 75 44 26 41 55 69 9 57 97 53 30 15
2023/2024561 23 92 41 38 35 76 6 62 15 12 118 43
2024/20252.752 125 97 23 54 53 187 262 161 202 275 1.049 264
2025/20266.288 666 474 570 610 1.118 249 688 329 598 481 371 134
2026/2027868 524 225 119 0 0 0 0 0 0 0 0 0
Totale 12.486